Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients’ Upper and Lower Airways after IV-Antibiotic Therapy

Table 2

Clinical and serological characteristics of included patients and healthy controls.

Metric and ordinal variables		Mean ± SD	Median	Range
Age (yrs)	17	25.5 ± 7.1	25.0	8–35
BMI (kg/m^2)	17	19.5 ± 3.6	19.2	14.7–29.3
FEV1 (l)/(% predicted)	17	1.9 ± 1.3 (57.9 ± 38.1)	1.3 (38.1)	0.8–5.7 (25–141)
MEF75/25 (l)/(% predicted)	13	1.4 ± 1.4 (36.9 ± 40.4)	0.7 (19.0)	0.3–4.6 (8.0–139.8)
ESR (mm/h)	18	34.3 ± 26.0	24.0	2–85
CRP (mg/l)	19	18.6 ± 30.5	5.7	0.5–108.1
Total IgG (g/l)	19	16.5 ± 4.7	17.4	9.5–27.8
Total IgE (kU/l)	18	324.3 ± 529.0	62.7	6.4–1568
SNOT-GAV-20
Prior to therapy	19	27.3 ± 13.7	26.0	6–56
After therapy	19	17.4 ± 10.6	19.0	3–44
Healthy controls
Age (yrs)	20	28.2 ± 7.4	25.0	23–48
BMI (kg/m^2)		21.9 ± 3.1	21.0	17.7–28.3
SNOT-20-GAV		4.7 ± 11.8	3.0	0–26